Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | GPR39 | O43194 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996234 | 0.88 | CNR1 (0.46) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1993250 | 0.88 | ROCK2 (0.50) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1997808 | 0.88 | PADI4 (0.44) | PADI4ROCK2CNR1HTR4ACHE | |
| SCHEMBL1991081 | 0.85 | RECQL (0.49) | HTR2AHTR2C | |
| SCHEMBL1993549 | 0.82 | LTA4H (0.41) | PADI4ROCK2CNR1HTR4 | |
| SCHEMBL1994502 | 0.81 | ROCK2 (0.44) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1996125 | 0.80 | PADI4 (0.47) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1992793 | 0.79 | PADI4 (0.45) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1992796 | 0.79 | PADI4 (0.45) | PADI4ROCK2CNR1ACHECNR2 | |
| SCHEMBL1992840 | 0.79 | KDM4E (0.46) | PADI4CNR1SSTR4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | PADI4 795/4885ROCK2 4260/4885CNR1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.